Argonaute RNA Secures £963.7k Seed Funding to Advance Gene-Silencing Therapeutics

Argonaute RNA Limited, a biotechnology company developing gene-silencing therapeutics, has raised £963.7k in a new seed funding round. The investment brings the company to an estimated post-money valuation of £11.2m. The allotment was completed on 25 February 2026 and officially filed on 11 March 2026.

Founded in July 2015, Argonaute RNA is officially registered in Cardiff while operating from a headquarters in Bristol city centre. The company specialises in RNA interference, a cellular mechanism that inhibits the expression of specific genes and prevents the production of disease-causing proteins.

The core problem Argonaute RNA addresses is the inherent instability of small interfering RNA when used as a drug in humans. The company has developed a proprietary platform to stabilise these molecules, allowing for safe and reliable gene silencing in different tissue cells. Their lead therapeutic programs target cardiovascular conditions, specifically severe familial hypercholesterolaemia. To bring these treatments to clinics, the company collaborates with strategic pharmaceutical partners to tackle medical needs that have historically been considered undruggable.

Operating with a highly specialised team, the company reported six employees in its latest financial accounts, while its professional network presence indicates a broader workforce of up to 14 staff members.

This new £963.7k seed injection builds upon a steady track record of early-stage backing. In July 2024, Argonaute RNA raised £1.75m in a round led by the Development Bank of Wales, with participation from Empirical Ventures, The Fink Family Office, and the Bristol Private Equity Club. Before that, the company secured £1.4m in 2021, a round that included strategic investment from pharmaceutical innovation partner CatSci Ltd to help develop the manufacturing strategy for their synthetic oligonucleotides.

The latest funding arrives during a highly selective period for the UK life sciences sector. According to recent data from the BioIndustry Association, UK biotech companies secured £1.8bn in venture capital in 2025, representing a 13.2 percent year-on-year decrease. The broader market has seen funding concentrated into a smaller number of high-conviction deals, alongside a complete absence of biotech initial public offerings for the third consecutive year.

Despite these macroeconomic constraints, the UK retains its position as Europe's largest biotech venture market. Argonaute RNA's successful raise demonstrates that early-stage companies developing advanced therapies and frontier technologies can still secure capital. With global pharmaceutical companies continuing to acquire UK biotech assets, proprietary platforms in the RNA and gene therapy space remain a strong focal point for strategic investment.